Pharmaceutical companies representatives

However, problems can and often do arise because the relationship between physician and pharmaceutical company is open to varying degrees of abuse. For example, the pharmaceutical company representative may practice selective disclosure when providing information. Without all the relevant information, the physician may not be able to adequately assess the suitability of the product for his patients use. This situation is complicated by the fact that every salesperson practices selective disclosure to some extent. It is often called "putting one s best foot forward." The difficulty lies in determining where one should draw the line. 

One of the pharmacists began to call on physicians so that he could promote the services face to face. The pharmacist met with some of the local pharmaceutical company representatives to find out which physicians should be identified as key targets for the promotional efforts. Also, the pharmacy created a physician newsletter entitled, Progress Notes, that would be sent every other month to key physicians. The format of the newsletter includes sections on new drug updates, clinical pearls, and message updates about Care-Rite Pharmacy. The first newsletter was dedicated to the Pharmacy Check-up Service. 

The pharmaceutical company representatives shall be adequately trained by their respective company cuid have sufficient scientific knowledge to be able to supply precise information that is as complete as possible about the drugs they represent. 

The pharmaceutical company representatives shall, each time they visit a health worker, provide him or her, or place at his or her disposal, with regard to each of the drugs they represent, a summary of the product s features, together with information about its price and, where appropriate, the subsidy conditions. 

The pharmaceutical company representatives shall provide the scientific department of their respective company with all information they receive from the hecdth workers they visit regarding the use of the drugs they promote, especially that relating to adverse reactions. 

Libraries. The library of a pharmaceutical company represents an educational benefit as well an indispensable tool. The attractions of a corporate library are not limited to its physical holdings, but also embrace the knowledge of its staff and the scope of its services. Large pharmaceutical companies maintain good collections that combine many valuable features of university science and public libraries. They keep as many as 10,000 books that include chemistry texts, monographs, and series. Even popular corporate histories like Barry Werth s 1994 The Billion Dollar Molecule appear on the shelves. 

Controllers must also have the resources and information necessary to enforce the safety constraints they have been assigned. Physicians need information about drug safety and efficacy that is independent from the pharmaceutical company representatives in order to adequately protect their patients. One of the first steps in performing an analysis of the drug safety control structure is to identify the contextual factors that can influence whether each component s responsibilities are carried out and the information required to create an accurate process model to support informed decision making in exercising the controls they have available to carry out their responsibilities. 

Japan is the third significant ethical pharmaceutical market, with two pharmaceutical companies representing 4% of total revenue for the top 20 companies in the world. Tlie market is as homogenous as that in the U.S., perhaps more so, but has a population and market size about half that in the U.S. In addition, it has been slow to freely interact with the larger pharmaceutical R D conununity, missing some of the opportunities and risks of the borderless access to markets and human capital. 

In Zimbabwe, the employment of unlicensed pharmaceutical sales representatives by some importing companies can perhaps be attributed to the fact that no import permit is required for importing registered dmg products. Therefore, once a company registers a product, any other company can also import and distribute that product using unregistered sales representatives. 

Approximately 30% to 40% of currently licensed drugs are targeted at GPCRs and thus represent a highly significant source of income for many pharmaceutical companies (80). In the specific context of chemokine receptors, it is clear that they are involved in a number of prominent pathologies and thus represent an important therapeutic target (81). For example, chemokines and their receptors lie at the center of all immune and inflammatory disorders and are responsible for the aberrant accumulation of leukocytes at inflamed sites in autoimmune conditions. In addition, over the past 12 years, it has become clear... 

The largest ten companies represent more than 90% of pharmaceutical sales. During the last 20 years, mergers have continued, and the last few years have seen even further consolidation of the pharmaceutical industry. One analyst reported in the Wall Street... 

The present review illustrates that UV-vis based process analytical technology is widely discussed, but published examples are still scarce. The pharmaceutical industry, driven by the FDA s PAT initiative, can be seen as a forerunner. This is reflected by the observation that many references in this chapter are (co-) authored by representatives from pharmaceutical companies like Glaxo Wellcome and GlaxoSmithKline, ° " ° Astra Zeneca, Novartis and Eli Lilly. ... 

---